(Q28200179)

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's Pooling Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Determinants of stroke after coronary artery bypass grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Stroke prevention: management of modifiable vascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Predictors of first stroke in Type 1 diabetes: The Fremantle Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Prospective study of single and multiple lacunar infarcts using magnetic resonance imaging: risk factors, recurrence, and outcome in 175 consecutive cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Cerebral infarction in diabetes: clinical pattern, stroke subtypes, and predictors of in-hospital mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

A comparison of risk factors for recurrent TIA and stroke in patients diagnosed with TIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Diabetes is an independent risk factor for in-hospital mortality from acute spontaneous intracerebral hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Meta-analysis of relation between cigarette smoking and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Smoking cessation and decreased risk of stroke in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Alcohol consumption and risk of stroke: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Physical activity and stroke risk: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Diabetes, hypertension, and cardiovascular disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Treatment of cardiovascular and renal risk factors in the diabetic hypertensive

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Hypertension management in type 2 diabetes mellitus: recommendations of the Joint National Committee VII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Development of diabetes is retarded by ACE inhibition in hypertensive patients--a subanalysis of the Captopril Prevention Project (CAPPP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

The treatment of hypertension in adult patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Statins for stroke prevention: disappointment and hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Favorable outcome of ischemic stroke in patients pretreated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Potentially reversible factors during the very acute phase of stroke and their impact on the prognosis: is there a large therapeutic potential to be explored?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Stroke in patients with diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes : the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Rapid progression of albumin excretion is an independent predictor of cardiovascular mortality in patients with type 2 diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Receptor-mediated regional sympathetic nerve activation by leptin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Leptin, but not adiponectin, predicts stroke in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Endocrine abnormalities and outcome of ischaemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Adipose tissue and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Cardiovascular Events in Diabetic and Nondiabetic Adults With or Without History of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Primary Prevention of Ischemic Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487

Cause of Stroke Recurrence Is Multifactorial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.487